Abstract: Sphingosine1-phosphate (S1P)， a bioactive sphingolipid produced by the metabolism of sphingomyelin ，is an important signaling regulator involved in tumor progression in multiple neoplasms. The formation of S1P is catalyzed by sphingosine kinases (SphKs)， coupled with S1P receptors (S1PR) to exert effects. In recent years, studies involving S1P and ovarian cancer suggest that S1P is highly expressed in ovarian cancer patients. S1P，who can promote the proliferation and metastasis of ovarian cancer cells, inhibit apoptosis, change the tumor-associated microenvironment, is involved in the regulation of key cellular processes that contribute to ovarian cancer initiation and progression. Moreover, agents（S1P，SphK1，S1PR，etc.） who block the S1P signaling pathway inhibit ovarian cancer cell growth or induce apoptosis. Hence, current evidence suggests that S1P may become a potential molecular target for ovarian cancer therapy. This article briefly reviews the physiological functions of S1P signaling pathway in ovarian cancer and the research progress of related drugs.

Key words: Sphingosine, Phosphoric acids, Ovarian neoplasms, Cell proliferation, Apoptosis, Therapy